Nuance Investments LLC lifted its position in shares of CVS Health Corp (NYSE:CVS) by 19.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 44,314 shares of the pharmacy operator’s stock after buying an additional 7,358 shares during the period. Nuance Investments LLC’s holdings in CVS Health were worth $3,604,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Fieldpoint Private Securities LLC increased its stake in shares of CVS Health by 333.3% during the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after buying an additional 1,000 shares during the period. Arcadia Investment Management Corp MI boosted its position in shares of CVS Health by 119.6% during the third quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock valued at $108,000 after purchasing an additional 726 shares in the last quarter. MPS Loria Financial Planners LLC bought a new stake in shares of CVS Health during the second quarter valued at approximately $119,000. Captrust Financial Advisors bought a new stake in shares of CVS Health during the second quarter valued at approximately $155,000. Finally, Howe & Rusling Inc. boosted its position in shares of CVS Health by 5,084.2% during the third quarter. Howe & Rusling Inc. now owns 1,970 shares of the pharmacy operator’s stock valued at $160,000 after purchasing an additional 1,932 shares in the last quarter. 80.81% of the stock is currently owned by institutional investors and hedge funds.
CVS has been the topic of several research reports. Loop Capital lowered their price target on CVS Health from $83.00 to $73.00 and set a “hold” rating on the stock in a report on Tuesday, November 7th. Morgan Stanley raised CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 price target on the stock in a report on Friday, January 5th. Needham & Company LLC upped their price target on CVS Health from $85.00 to $88.00 and gave the company a “buy” rating in a report on Tuesday, January 2nd. SunTrust Banks upped their price target on CVS Health to $90.00 and gave the company a “buy” rating in a report on Friday, January 5th. Finally, Leerink Swann set a $85.00 price objective on CVS Health and gave the company a “buy” rating in a research report on Friday. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company’s stock. CVS Health presently has an average rating of “Buy” and an average target price of $87.77.
In related news, EVP Lisa Bisaccia sold 29,445 shares of the stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the transaction, the executive vice president now directly owns 15,556 shares of the company’s stock, valued at $1,166,700. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.61% of the company’s stock.
Shares of CVS Health Corp (CVS) opened at $69.87 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.02 and a quick ratio of 0.52. The company has a market capitalization of $70,462.84, a PE ratio of 10.80, a price-to-earnings-growth ratio of 1.16 and a beta of 0.93. CVS Health Corp has a 1 year low of $66.45 and a 1 year high of $84.00.
CVS Health (NYSE:CVS) last released its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.04. The firm had revenue of $48.39 billion during the quarter, compared to analyst estimates of $47.54 billion. CVS Health had a return on equity of 17.21% and a net margin of 3.58%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.71 earnings per share. sell-side analysts expect that CVS Health Corp will post 6.47 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, February 2nd. Stockholders of record on Wednesday, January 24th were paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.86%. The ex-dividend date was Tuesday, January 23rd. CVS Health’s dividend payout ratio (DPR) is 30.91%.
COPYRIGHT VIOLATION NOTICE: “CVS Health Corp (CVS) Stake Raised by Nuance Investments LLC” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/02/13/cvs-health-corp-cvs-position-raised-by-nuance-investments-llc.html.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.